Steroid sparing in vasculitis: Myth or reality?

Best Pract Res Clin Rheumatol. 2023 Mar;37(1):101843. doi: 10.1016/j.berh.2023.101843. Epub 2023 Jun 22.

Abstract

Glucocorticoids are the cornerstone of therapy for all forms of vasculitis. However, glucocorticoid treatment carries with it the risk of glucocorticoid toxicity. Recent research efforts in vasculitis have emphasized investigation into strategies that reduce glucocorticoid exposure. These strategies include the adoption of rapid-acting steroid-sparing agents, reduced-dose glucocorticoid induction regimens, the early introduction of steroid-sparing agents for maintenance therapy, and the extension of maintenance therapy to minimize glucocorticoid exposure associated with disease relapse. These are critical advances to move us toward the goal of glucocorticoid-free treatment of vasculitis. The evidence supporting each of these strategies and directions for future research are explored.

Keywords: Avacopan; Glucocorticoids; Steroid sparing; Toxicity; Vasculitis.

Publication types

  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Steroids / therapeutic use
  • Vasculitis* / drug therapy

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Steroids